Want Diversified Upside in Biotechnology? Check out LABU Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering ...

Alnylam Stock Soars 65%: Find Out What's Behind the Gains Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff ...

Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Arrowhead Pharmaceuticals’ RNA interference (RNAi) therapeutic lowered triglycerides in patients with a rare metabolic disease that prevents the body from breaking down fats during a phase 3 trial.

ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase ...